Stock Watch: Pandemic Lessons For Smaller Commercial Biotechs
Neurocrine And Clovis Are Still Deep In Pandemic Pressures
Recently launched branded drugs prescribed by specialist physicians and marketed by smaller commercial-stage biotech companies remain in the eye of the pandemic storm.
You may also be interested in...
An early high for Pfizer with its strong first-quarter results was followed by patent waiver worries. At the other end of the spectrum, Esperion reminded us of the challenges in making a commercial success as a small biopharma firm in the pandemic.
Many of the many biotech companies that raised money to develop and repurpose their molecules to address the pandemic have started to unwind those efforts. What will this mean for the sector’s valuation?
The stock price performances of the top two coronavirus vaccine producers are inversely correlated to their sales and pipelines. There seems to be an expectation of declining coronavirus vaccine sales for some, but not for others.